Cortes, Jorge E. http://orcid.org/0000-0002-8636-1071
de Lima, Marcos
Dombret, Hervé
Estey, Elihu H.
Giralt, Sergio A.
Montesinos, Pau
Röllig, Christoph
Venditti, Adriano
Wang, Eunice S.
Funding for this research was provided by:
Pfizer
Article History
Received: 12 August 2020
Accepted: 5 October 2020
First Online: 15 October 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Jorge E. Cortes received research funding to his institution and consulting honoraria from Pfizer, Novartis, Astellas, Daiichi Sankyo, Jazz Pharmaceuticals, Takeda, and Celgene. Marcos de Lima was a consultant and served on advisory boards for Celgene, Incyte, Kiadis Pharma, Partner Therapeutics, Pfizer, and Pharmacyclics. Hervé Dombret, Elihu H. Estey, and Sergio A. Giralt have no conflicts of interest to declare. Pau Montesinos was a consultant and served on advisory boards for AbbVie, Agios, Astellas, Celgene, Daiichi Sankyo, Incyte, Janssen, Karyopharm, Novartis, Oryzon, Pfizer, Teva, and Tolero, and received research funding to his institution from Astellas, Celgene, Daiichi Sankyo, Janssen, Karyopharm, Novartis, Pfizer, and Teva. Christoph Röllig received research funding to his institution and consulting honoraria from AbbVie, Amgen, Astellas, Bayer, BMS, Celgene, Daiichi Sankyo, Janssen, Jazz, Novartis, Pfizer, Roche, and Takeda. Adriano Venditti was a consultant and served on advisory boards for Novartis, Pfizer, Astellas, and Daiichi Sankyo. Eunice S. Wang has received consultancy fees from Abbvie, Amgen, Astellas, Daiichi Sankyo, Genentech, Jazz, Kite Pharmaceuticals, Kura Oncology, Macrogenics, Pfizer, PTC Therapeutics, and Stemline, and has served as a speaker for Dava Oncology and Stemline, Pfizer.